Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline

S Branford, DT Yeung, WT Parker… - Blood, The Journal …, 2014 - ashpublications.org
In chronic myeloid leukemia (CML) patients, a breakpoint cluster region–Abelson (BCR-
ABL1) value> 10% at 3 months of therapy is statistically associated with poorer outcome, yet …

Analyzing molecular response in chronic myeloid leukemia clinical trials: pitfalls and golden rules

J Guilhot, C Preudhomme, FX Mahon, F Guilhot - Cancer, 2015 - Wiley Online Library
Clinical trials of chronic myeloid leukemia frequently rely on molecular markers as
surrogates for clinical endpoints. Studies suggest that early molecular response (EMR) is a …

Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3‐and 6‐month time …

S Lapusan, A Yong, BN Savani… - European Journal of …, 2015 - Wiley Online Library
Patients with chronic myeloid leukemia in chronic phase who achieve early molecular
response (EMR; generally defined as BCR‐ABL≤ 10% on the International Scale at 3 or 6 …

Nowe metody diagnostyczne w prognozowaniu i śledzeniu odpowiedzi na leczenie inhibitorami kinaz tyrozynowych przewlekłej białaczki szpikowej

J Wącław, T Sacha - acta haematologica polonica, 2016 - Elsevier
Techniques of molecular biology are of key importance in diagnostics and monitoring of
tyrosine kinase inhibitors (TKIs) treatment response of chronic myeloid leukemia (CML) …

Recent developments in diagnostics and monitoring of tyrosine kinase inhibitors treatment response of chronic myeloid leukemia

J Wącław, T Sacha - Acta Haematologica Polonica, 2016 - journals.viamedica.pl
Techniques of molecular biology are of key importance in diagnostics and monitoring of
tyrosine kinase inhibitors (TKIs) treatment response of chronic myeloid leukemia (CML) …